Close Menu

NEW YORK — Novacyt on Monday reported a 906 percent year-over-year increase in unaudited revenues for the first half of 2020, driven by strong demand for COVID-19 testing.

For the six months ended 30 June, the Paris-based company reported unaudited revenues of €72.4 million ($82 million) compared to €7.2 million for the first half of 2019. The firm said it booked 91 percent of the revenues in the second quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.